ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Response Criteria"

  • Abstract Number: 0840 • ACR Convergence 2023

    Head-to-Head Comparison of TLL-018 and Tofacitinib in Patients with Active Rheumatoid Arthritis: Final Results from a Phase IIa Study

    Xiaofeng Zeng1, chanyuan wu2, Jiankang Hu3, SHENGYUN LIU4, Zhenyu Jiang5, Jingyang Li6, Xiaoxia Wang7, Ju Liu8, Chaofan Yuan9, Guang Yang10 and Chris Liang10, 1Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 3Pingxiang People’s Hospital, PingXiang, China, 4The First Affiliated Hospital Of Zhengzhou University, Zhengzhou, China, 5The First Hospital of Jilin University, Changchun, China, 6Zhuzhou Central Hospital, Zhuzhou, China, 7Second Hospital of Shanxi Medical University, Taiyuan, China, 8Jiujiang No. 1 People’s Hospital, JiuJiang, China, 9Hangzhou Highlightll Pharmaceutical Co., Ltd, Beijing, China, 10Hangzhou Highlightll Pharmaceutical Co., Ltd, HangZhou, China

    Background/Purpose: None of the currently approved treatments for rheumatoid arthritis (RA) can achieve ACR50 in >50% of the patients, and 5 – 20% of the…
  • Abstract Number: 0974 • ACR Convergence 2023

    Validation of Boolean 2.0 Criteria for Assessing Remission and Predicting Quality of Life in Korean Patients with Rheumatoid Arthritis Undergoing Targeted Therapy

    Soo-Kyung Cho1, Yeo-Jin Song1, Jungyong Han2, Hye Won Kim3, Eunwoo Nam3 and Yoon-Kyoung Sung1, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 3Hanyang University Institute for Rheumatology Research, Seoul, South Korea

    Background/Purpose: The management of rheumatoid arthritis (RA) focuses on achieving remission as a treatment goal. The updated ACR/EULAR remission definition (Boolean criteria 2.0) has raised…
  • Abstract Number: 1172 • ACR Convergence 2023

    Relapse Rate After Glucocorticoid-free Remission in Idiopathic Inflammatory Myopathies with Validation of the International Myositis Assessment & Clinical Studies Group (IMACS) Criteria for Remission and Relapse

    Hideaki Tsuji1, Fabricio Espinosa-Ortega2, Maryam Dastmalchi2, Ingrid Lundberg2 and Karin Lodin3, 1Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 2Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, 3Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Huddinge, Sweden

    Background/Purpose: Our aim was to explore whether maintenance of remission in patients with idiopathic inflammatory myopathy (IIM) depends on glucocorticoids (GCs) after achieving remission. Therefor…
  • Abstract Number: 1423 • ACR Convergence 2023

    Impact of Upadacitinib on Enthesitis and Dactylitis by Location in Patients with Psoriatic Arthritis and an Inadequate Response to Biologic DMARDs from the SELECT-PsA 2 Trial

    Laura Coates1, Catherine Bakewell2, Majed Khraishi3, Shirley Chen4, Tianming Gao4, Arathi Setty4, Heather Jones5, Sandra Ciecinski4 and Eduardo Mysler6, 1University of Oxford, Oxford, United Kingdom, 2Intermountain Healthcare Medical Group, Salt Lake City, UT, 3Memorial University of Newfoundland, St. John's, NL, Canada, 4AbbVie, Inc., North Chicago, IL, 5AbbVie, Inc., Mettawa, IL, 6Organización Medica de Investigación, Buenos Aires, Argentina

    Background/Purpose: Enthesitis and dactylitis are associated with reduced quality of life and greater impairment in daily activities. In the SELECT-PsA 2 phase 3 trial, the…
  • Abstract Number: 2143 • ACR Convergence 2023

    Efficacy of Filgotinib in Patients with Rheumatoid Arthritis: Week 156 Results from a Long-term Extension Study

    Maya Buch1, Daniel Aletaha2, Roberto F. Caporali3, Bernard G. Combe4, Hendrik Schulze-Koops5, Jacques-Eric Gottenberg6, Yoshiya Tanaka7, Ricardo Blanco8, Tsutomu Takeuchi9, Edmund V. Ekoka Omoruyi10, Katrien Van Beneden11, Vijay Rajendran12, Chris Watson13, Francesco De Leonardis14 and Paul Emery15, 1University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, 2Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria, 3Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, 4Department of Rheumatology, Montpellier University, Montpellier, France, 5Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians–University Munich, Munich, Germany, 6Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, 7University of Occupational and Environmental Health, Kitakyushu, Japan, 8Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 9Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, 10Biostatistics, Galapagos NV, Mechelen, Belgium, 11Medical Safety, Galapagos NV, Mechelen, Belgium, 12Clinical Research, Galapagos NV, Mechelen, Belgium, 13Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, 14Medical Affairs, Galapagos GmbH, Basel, Switzerland, 15Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: In the treatment of RA, JAK inhibitors are a valuable option to meet remission or low disease activity (LDA) treatment targets following an inadequate…
  • Abstract Number: 2334 • ACR Convergence 2023

    Remission Attainment in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period

    Ronald van Vollenhoven1, Eric Morand2, Richard A. Furie3, Kenneth Kalunian4, Raj Tummala5, Gabriel Abreu6, Hussein Al-Mossawi7 and Catharina Lindholm6, 1Amsterdam University Medical Centers, Amsterdam, Netherlands, 2Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, 3Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 4University of California San Diego, La Jolla, CA, 5BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 6BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 7BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

    Background/Purpose: In patients with SLE, remission is an established therapeutic goal associated with reduced damage accrual and flares, and improved health-related quality of life.1 Here,…
  • Abstract Number: 2486 • ACR Convergence 2023

    Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG a And/or Two BILAG B Scores?

    Ewa Olech1 and Joan Merrill2, 1IQVIA, Rheumatology Consultants, PLLC, Las Vegas, NV, 2Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: High placebo response rates have challenged interpretation of clinical trial results in SLE and may have contributed to failure of some effective treatments. One…
  • Abstract Number: 2551 • ACR Convergence 2023

    Remission and Low Disease Activity (LDA) in Patients with SLE Treated with Belimumab (BEL): Results from a Large Integrated Analysis

    Ioannis Parodis1, Julius Lindblom1, Roger A. Levy2, Margherita Zen3, Nursen Cetrez1, Alvaro Gomez4, Shereen Oon5, Christine Henning6, Munther Khamashta7, Holly A. Quasny8, Deven Chauhan9, Anca Askanase10, Ronald van Vollenhoven11 and Mandana Nikpour12, 1Karolinska Institutet, Stockholm, Sweden, 2GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, 3University of Padua, Division of Rheumatology, Department of Medicine, Padua, Italy, 4Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, 5University of Melbourne at St Vincent’s Hospital, Departments of Rheumatology and Medicine, Fitzroy, Australia, 6GlaxoSmithKline, US Medical Affairs, Durham, NC, 7GSK Gulf, Medical Affairs Department, Dubai, United Arab Emirates, 8GlaxoSmithKline, Research & Development, Durham, NC, 9GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, 10Columbia University Medical Center, New York, NY, 11Amsterdam Rheumatology and Immunology Center and Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands, 12The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia

    Background/Purpose: A key treatment goal in SLE management is the attainment of remission or LDA,1 for which various definitions exist, including “Definitions of Remission in…
  • Abstract Number: 0294 • ACR Convergence 2022

    Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years from the SELECT-BEYOND Study

    Roy Fleischmann1, Sebastian Meerwein2, Christina Charles-Schoeman3, BERNARD COMBE4, Stephen Hall5, Nasser Khan6, Kyle Carter7, Heidi Camp8 and Andrea Rubbert-Roth9, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2AbbVie Deutschland GmbH & Co KG, LUDWIGSHAFEN, Germany, 3Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, 4Montpellier University, Montpellier, France, 5Emeritus Research and Monash University, Melbourne, Australia, 6AbbVie, Inc., Abbott Park, IL, 7AbbVie, Inc., North Chicago, IL, 8Abbvie, Winnetka, IL, 9Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland

    Background/Purpose: To evaluate the long-term efficacy and safety of upadacitinib (UPA) over 5 yrs among patients with rheumatoid arthritis (RA) in a long-term extension (LTE)…
  • Abstract Number: 2110 • ACR Convergence 2022

    Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population

    Laure Gossec1, Mohamed Sharaf2, Elke Theander3, Marlies Neuhold4, Paul Bergmans5, May Shawi6, Michelle Perate7, Christine Contré8 and Laura Coates9, 1Sorbonne Université, Paris, France, 2Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, 3Formerly at Janssen Scientific Affairs, LLC, Solna, Sweden, 4Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, 5Formerly at Janssen, Breda, Netherlands, 6Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 7Janssen Scientific Affairs, LLC, Horsham, PA, 8Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, 9Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: The Phase 3b COSMOS study (NCT03796858) demonstrated the efficacy and safety of guselkumab (GUS), an IL-23 p19 subunit inhibitor, in patients (pts) with psoriatic…
  • Abstract Number: 0295 • ACR Convergence 2022

    Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-NEXT Study

    Gerd Burmester1, Filip Van den bosch2, John Tesser3, Anna K Shmagel4, Yuanyuan Duan4, Nasser Khan5, Heidi Camp6 and Alan Kivitz7, 1Charité University Medicine Berlin, Berlin, Germany, 2Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, 3Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 4AbbVie, Inc., North Chicago, IL, 5AbbVie, Inc., Abbott Park, IL, 6Abbvie, Winnetka, IL, 7Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA

    Background/Purpose: In the phase 3 SELECT-NEXT study, upadacitinib (UPA) demonstrated efficacy at wk 12 and sustained efficacy up to wk 60 in patients with rheumatoid…
  • Abstract Number: 2139 • ACR Convergence 2022

    Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial

    Iain B McInnes1, Philipp Sewerin2, Mohamed Sharaf3, Michela Efficace4, May Shawi5, Michelle Perate6, Miriam Zimmermann7 and Laura Coates8, 1Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 2Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, 3Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, 4Janssen Cilag SpA, Imperia, Italy, 5Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 6Janssen Scientific Affairs, LLC, Horsham, PA, 7Janssen Scientific Affairs, LLC, Zug, Switzerland, 8Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody targeting the IL-23 p19 subunit. In the Phase 3b COSMOS trial (NCT03796858), GUS significantly improved disease signs/symptoms…
  • Abstract Number: 0348 • ACR Convergence 2022

    Significant Improvement in Cutaneous Lupus Erythematosus with or Without Systemic Lupus Erythematosus with Belimumab Use – a Systematic Review and Meta-Analysis

    Rachel Kneeland1, Daniel Montes1, Justin endo1, Bridget Shields1, Christie Bartels2 and Shivani Garg3, 1University of Wisconsin, School of Medicine and Public Health, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Madison, WI, 3University of Madison, School of Medicine and Public Health, Madison, WI

    Background/Purpose: Cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE), can be debilitating and cause significant scarring and psychological distress. Belimumab, a monoclonal…
  • Abstract Number: 0417 • ACR Convergence 2022

    Treating Spondyloarthritis Early: Does It Matter? Results from a Systematic Literature Review

    Dafne Capelusnik1, Diego Benavent2, Désirée van der Heijde3, Robert Landewé4, Denis Poddubnyy5, Astrid van Tubergen6, Louise Falzon7, Victoria Navarro-Compán8 and Sofia Ramiro9, 1Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, 2La Paz University Hospital, Madrid, Spain, 3Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, 4Amsterdam University Medical Centers, Amsterdam, Netherlands, 5Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 6Maastricht UMC+, Maastricht, Netherlands, 7Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, 8Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 9Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: The ASAS-SPEAR (SPondyloarthritis EARly definition) project aims to develop a consensual definition of early SpA. Therefore, it is important to know whether treatment earlier…
  • Abstract Number: 0474 • ACR Convergence 2022

    Utility of Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Study of 471 Patients

    Fabricio Benavides Villanueva1, Cristina Corrales1, Javier Loricera2, Monica Calderón-Goercke1, Clara Moriano3, Santos Castañeda4, FRANCISCO JAVIER NARVAEZ5, Vicente Aldasoro6, Olga Maiz7, Rafael Melero8, Juan Ignacio Villa9, Paloma Vela-Casampere10, Susana Romero Yuste11, José Luis Callejas12, Eugenio De Miguel13, Eva Galíndez-Agirregoikoa14, Francisca Sivera15, Jesús Carlos Fernández-López16, Carles Galisteo17, Ivan Ferraz Amaro18, JULIO SANCHEZ MARTIN1, Lara Sánchez-Bilbao1, Jose Luis Hernández1, Miguel Angel Gonzalez Gay19 and Ricardo Blanco2, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Complejo Asistencial Universitario de León, León, Spain, 4Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 5Hospital de Bellvitge, Barcelona, Spain, 6Hospital Universitario de Navarra, Pamplona, Spain, 7Hospital Universitario de Donostia, San Sebastián, Spain, 8Complexo Hospitalario Universitario de Vigo, Vigo, Spain, 9Hospital Sierrallana, Torrelavega, Spain, 10Hospital General Universitario Alicante, Alicante, Spain, 11Complexo Hospitalario Universitario, Pontevedra, Spain, 12Hospital San Cecilio, Granada, Andalucia, Spain, 13Hospital Universitario La Paz, Madrid, Spain, 14Basurto University Hospital, Bilbao, Spain, 15Hospital Universitario de Elda, San Vicente del Raspeig, Spain, 16Complejo H. Universitario de A Coruña, A Coruña, Spain, 17Hospital Parc Tauli,, Sabadel, Spain, 18Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, 19Hospital Universitario Marques de Valdecilla, Lugo, Spain

    Background/Purpose: Tocilizumab (TCZ) has shown to be useful in the treatment of large-vessel vasculitis, including giant cell arteritis (GCA). There is general agreement on the…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology